The Million Hearts initiative, with its goal of preventing a million cardiovascular events in 5 years, requires sustained efforts by cardiologists in conjunction with public health experts to achieve success, explained Janet Wright, MD, FACC, the program’s executive director.
The Million Hearts initiative, with its goal of preventing a million cardiovascular events in 5 years, requires sustained efforts by cardiologists in conjunction with public health experts to achieve success, explained Janet Wright, MD, FACC, the program’s executive director.
Transcript (slightly modified)
How has your experience as a cardiologist shaped your approach to leading Million Hearts?
I actually was an interventional and clinical cardiologist before working at ACC, and now with Million Hearts. Really what I see is the whole arc of care, and actually the arc of life. By that I mean, in cardiology we have awesome contributions from interventionists who really save people, bring them back from the brink. We need their continued work, life-saving work.
In addition, we need both those interventionists and other types of cardiologists to use their teams to improve prevention, to keep people from ever having to end up in the cath lab, or in the emergency room. It’s entirely possible with the systems that we have and the systems that we’re building.
But I’d go a step further, and that’s really been a lesson for me in Million Hearts, is to incorporate and collaborate closely with public health. We don’t actually, thank goodness, live in our healthcare settings — often cardiologists feel like they live in a healthcare setting, but we live in communities, we live in towns, we live in connection with others, of course, in our community. So, bringing in the public health actions will actually help keep people healthy and begin to impact the number that end up needing some sort of cardiovascular care and hopefully reducing the number who end up in a cardiovascular emergency.
We are strong believers in Million Hearts that it is a public health—healthcare interaction, and in 2022 we’ll be focusing on high-priority populations, like African Americans with hypertension, or individuals with mental health and substance use who also smoke cigarettes, and certainly those who have already had a cardiovascular event, making sure that they get the medications, that they get cardiac rehab, and healthy lifestyles.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More